Oramed Pharmaceuticals (FRA:OJU1) ROCE %: -6.26% (As of Mar. 2026)


FRA:OJU1 Oramed Pharmaceuticals Inc FRA:OJU1
34 GF Score
Price €4.14
! 5 Warning Signs
View Full Analysis

What is Oramed Pharmaceuticals ROCE %?

Oramed Pharmaceuticals FRA:OJU1 +4.55% 34 ROCE % is -6.26% as of Mar. 2026. GuruFocus rates FRA:OJU1 with a GF Score™ of 34/100. The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Oramed Pharmaceuticals's annualized ROCE % for the quarter that ended in Mar. 2026 was -6.26%.

Oramed Pharmaceuticals  (FRA:OJU1) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Oramed Pharmaceuticals ROCE % Related Terms

Oramed Pharmaceuticals ROCE % Historical Data

* Premium members only.

The historical data trend for Oramed Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oramed Pharmaceuticals ROCE % Chart

Oramed Pharmaceuticals Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -30.06 -28.41 4.35 -9.71 39.74

Oramed Pharmaceuticals Quarterly Data
May21 Aug21 Nov21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.14 33.94 126.78 18.41 -6.26
FRA:OJU1
34GF Score
Oramed Pharmaceuticals Inc FRA:OJU1
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oramed Pharmaceuticals ROCE % Calculation

Oramed Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=64.327/( ( (148.29 - 5.429) + (197.158 - 16.299) )/ 2 )
=64.327/( (142.861+180.859)/ 2 )
=64.327/161.86
=39.74 %

Oramed Pharmaceuticals's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-12.66/( ( (197.158 - 16.299) + (232.553 - 9.137) )/ 2 )
=-12.66/( ( 180.859 + 223.416 )/ 2 )
=-12.66/202.1375
=-6.26 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -6.26% mean?
Oramed Pharmaceuticals (FRA:OJU1) has a ROCE % of -6.26% as of Mar. 2026.
Is Oramed Pharmaceuticals' ROCE % too high?
Oramed Pharmaceuticals' current ROCE % is -6.26%. Overall, Oramed Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Oramed Pharmaceuticals' ROCE % compare to EQ and HUMA?
Oramed Pharmaceuticals' ROCE % of -6.26% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Oramed Pharmaceuticals's current ROCE % is -6.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oramed Pharmaceuticals stock overvalued right now?
Oramed Pharmaceuticals (FRA:OJU1) has a current ROCE % of -6.26%. The current ROCE % is -6.26%. Oramed Pharmaceuticals' overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Oramed Pharmaceuticals (FRA:OJU1), the current ROCE % is -6.26% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oramed Pharmaceuticals Business Description

Address 1185 Avenue of the Americas, Third Floor, New York, NY, USA, 10036
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.
34GF Score

Get the complete analysis for FRA:OJU1

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.14
Price